Related content

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas

By Desjardins Annick   Quinn Jennifer   Vredenburgh James   Sathornsumetee Sith   Friedman Allan   Herndon James   McLendon Roger   Provenzale James   Rich Jeremy   Sampson John   Gururangan Sridharan   Dowell Jeannette   Salvado August   Friedman Henry   Reardon David  

Journal of Neuro-Oncology, Vol. 83, Iss. 1, 2007-05 ,pp. : 53-60

Springer Publishing Company

Access to resources Recommend Favorite

Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects

By Bolton Ann   Peng Bin   Hubert Martine   Krebs-Brown Axel   Capdeville Renaud   Keller Urs   Seiberling Michael  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 2, 2004-02 ,pp. : 102-106

Springer Publishing Company

Access to resources Recommend Favorite

Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect

By Puisset F.   Chatelut E.   Sparreboom A.   Delord J.-P.   Berchery D.   Lochon I.   Lafont T.   Roché H.  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 2, 2007-07 ,pp. : 305-308

Springer Publishing Company

Access to resources Recommend Favorite

Keratoacanthomas associated with imatinib mesylate

By Balagula Yevgeniy   Busam Klaus J.   Carvajal Richard D.   Wolchok Jedd D.   Myskowski Patricia L.  

Acta Oncologica, Vol. 50, Iss. 4, 2011-05 ,pp. : 593-595

Informa Healthcare

Access to resources Recommend Favorite

The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation

By Imai Yasuo   Yoshimori Mayumi   Fukuda Kazunori   Yamagishi Hidetsugu   Ueda Yoshihiko  

Oncology Reports, Vol. 27, Iss. 6, 2012-06 ,pp. : 1703-1709

Spandidos Publications

Access to resources Recommend Favorite